Eli Lilly and Company (NYSE:LLY) Shares Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.

Eli Lilly and Company Stock Up 0.2 %

LLY opened at $776.94 on Thursday. The stock has a market capitalization of $736.33 billion, a P/E ratio of 66.35, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The business has a 50 day simple moving average of $818.04 and a 200-day simple moving average of $813.77. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the company earned $2.58 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,002.80.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. raised its stake in Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Nordea Investment Management AB lifted its stake in Eli Lilly and Company by 13.7% during the fourth quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock worth $887,014,000 after purchasing an additional 138,835 shares during the last quarter. Legacy Wealth Management LLC MS acquired a new position in Eli Lilly and Company in the fourth quarter worth $215,000. CWA Asset Management Group LLC increased its stake in Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after purchasing an additional 724 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. raised its holdings in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Neville Rodie & Shaw Inc. now owns 15,031 shares of the company's stock worth $11,604,000 after purchasing an additional 97 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.